China's growing biotech prowess has become a real threat to the industry in the US in recent years. Moves by the Trump administration could weaken the US market further, according to several experts ...

The pharma industry has urged Bulgaria to reform drug pricing and clawbacks, warning current policies threaten patient access and foreign investment.

A panel of industry leaders emphasize the importance of early engagement with payers, real-world evidence, and value-based ...

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.

Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever.

As the markets for weight-loss drugs develop, pharma companies are having to adapt in search of the next big thing.

Let’s dig into the relative performance of Medpace (NASDAQ:MEDP) and its peers as we unravel the now-completed Q1 drug ...

Toy prices are rising at their fastest pace on record, the result of stiff new tariffs in an industry where 3 out of 4 items ...

Discover why NAGE's Tru Niagen leads the NAD+ market, backed by health trends, growth potential, and a 20%+ stock upside.

Drug maker Shanghai Henlius traces its history to 1992, when four ambitious young entrepreneurs formed Fosun Group to seize ...